“Some of my proudest moments as a researcher have been when I have been able to solve problems by going back to my notes to figure out the cause.”

👋 Meet Anton Rydberg and find out how applying a scientific mindset has value in both research and training.

🔗 www.fluicell.com/people/anton...

🔬 Last week we had the great pleasure of opening a new part of our lab at Fluicell focused on extended tissue and cell culture studies. This new space further enhances our ability to analyze tissue development, cell function and cell survivability over time.

👋Join us in welcoming Rosa Lacordaire and Charlotte Cany from @espciparispsl.bsky.social who are doing a research internship with us.

Supporting young researchers is an important part of Fluicell’s commitment to building the future of life science, and we’re excited to follow their progress.

We are excited to announce that we are partnering with Ambusol to create groundbreaking new ways to treat cancer. Leveraging our microfluidic technology, we are developing a novel type of device for high precision drug delivery directly to the tumor.

🔗 www.fluicell.com/news/fluicel...

🚀 We are excited to announce that we have received funding from Breakthrough T1D for a collaboration to develop type 1 diabetes tissue therapeutics.

The collaboration combines our Nexocyte platfom with unique stem cell material to build designer islets for type 1 diabetes treatment.

🧪 Researchers at @uofcalifornia.bsky.social have discovered new ways to selectively target specific voltage-gated sodium channels, affecting neuronal excitability. Their results can enable more precise ways to treat epilepsy and other neurological conditions.

🔗 www.fluicell.com/news/selecti...

We are excited to announce that our technology for generating three dimensional biological tissues has been granted a patent in the EU. The technology is the foundation for our tissue-based products for regenerative medicine and drug development targeting type 1-diabetes and cardiac disease.

Can light be a tool for labeling living cells? In a new study from researchers at @harvard.edu and Chinese Academy of Medical Sciences, Sarah Innes-Gold et al. present a method for light-activated cell labeling with high precision. Read more on our website.

🔗 www.fluicell.com/news/scienti...

🧪 On March 12, the BIRDIE consortium is gathering experts in organoids, organ-on-chip technology and kidney disease to discuss how andvanced in vitro models can transform drug development and biomedical research.

👉 birdieproject.eu/2025/02/07/f...

#OrganOnChip #Science #Bioprinting #KidneyDisease

Cardiovascular diseases are responsible for one third of all global deaths but represent only five percent of newly approved drugs.

Using our human tissue technology, we are creating next-generation research solutions to transform the way we treat heart disease.

👉 www.fluicell.com/pipeline/hea...

To measure neuron activation, Jové et al. used our open volume microfluidic platform BioPen to deliver blood and blood components directly to the tip of the mosquito stylet. The intriguing results show how neurons respond selectively to specific blood components.
#microfluidics #science

🌟 This past Friday we said goodbye to our interns Claire and Rachel from ESPCI, Paris, with a not so traditional Lucia celebration.

🙌 It has been an absolute privilege and a great joy to have you on our team and we wish you the best of luck on your journey ahead.

💜 We are excited to announce that a patent covering our unique microfluidic bioprinting technology has been granted in the EU. The patent is an important step forward in our mission to provide the next generation of tissue solutions for drug development and regenerative medicine.
#bioprinting